---
title: 'Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum,
  affective, behavioural, tic and other psychiatric disorders treated with aripiprazole:
  results of the TDM-VIGIL pharmacovigilance study'
date: '2024-11-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39487894/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241103172131&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Aripiprazole is approved for various severe mental disorders in adults
  and adolescents. However, off-label prescribing is common, especially in children
  and adolescents (youth) in whom aripiprazole therapeutic serum level reference ranges
  are lacking for any disorders. The aim of the study was to evaluate the relationship
  between aripiprazole dose and serum concentrations and provide further knowledge
  on the use of aripiprazole in order to improve drug safety and effectiveness in
  the ...
disable_comments: true
---
Aripiprazole is approved for various severe mental disorders in adults and adolescents. However, off-label prescribing is common, especially in children and adolescents (youth) in whom aripiprazole therapeutic serum level reference ranges are lacking for any disorders. The aim of the study was to evaluate the relationship between aripiprazole dose and serum concentrations and provide further knowledge on the use of aripiprazole in order to improve drug safety and effectiveness in the ...